ALX Oncology says Phase 2 ASPEN-06 study shows 40.3% response rate for evorpacept combo in HER2-positive gastric cancer

Bitget2026/09/28 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ALX Oncology reported already-published Phase 2 ASPEN-06 data in Nature Medicine for evorpacept in previously treated HER2-positive gastric cancer.
The regimen delivered stronger tumor shrinkage and longer-lasting benefit than standard therapy, with the largest gains in a biomarker-defined subgroup.
Findings supported CD47 expression as a potential patient-selection marker, reinforcing the company’s biomarker-driven development strategy.
ALX chose not to pursue a U.S. registrational Phase 3 path in gastric cancer, shifting focus toward potential partnerships for that program.
Management kept its mid-2027 target for a topline readout from 80 patients in the ongoing Phase 2 ASPEN-09-Breast trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834549) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ALX Oncology says Phase 2 ASPEN-06 study shows 40.3% response rate for evorpacept combo in HER2-positive gastric cancer

You may also like

Crypto prices